UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101

Anti-cancer agents in medicinal chemistry, 2016-01, Vol.16 (1), p.20

2016

Link zum Volltext

Verfügbarkeit prüfen

Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity

The Journal of clinical investigation, 2022-08, Vol.132 (16)

2022

Link zum Volltext

Verfügbarkeit prüfen

Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy

Antibodies (Basel), 2018-02, Vol.7 (1), p.11

2018

Link zum Volltext

Verfügbarkeit prüfen

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

Journal of hematology and oncology, 2018-02, Vol.11 (1), p.32-32, Article 32

2018

Link zum Volltext

Verfügbarkeit prüfen

Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11

Antibodies (Basel), 2018-08, Vol.7 (3), p.32

2018

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy is getting 'smarter'

Future oncology (London, England), 2015-02, Vol.11 (4), p.549-552

Mehrling, Thomas

2015

Link zum Volltext

Verfügbarkeit prüfen

DDRE-33. PRECLINICAL THERAPEUTIC EFFICACY OF THE NOVEL BLOOD BRAIN BARRIER PENETRANT ATR INHIBITOR LR02 IN GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi81-vi81

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT023: Dose escalation of tinostamustine in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT023-CT023

2019

Link zum Volltext

Verfügbarkeit prüfen

Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity

The Journal of clinical investigation, 2022-08, Vol.132 (16), p.1-15

2022

Link zum Volltext

Verfügbarkeit prüfen

Edo- S101, a New Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Has Superior Activity Against Myeloma and B Cell Lymphoma and Strong Synergy with Proteasome Inhibitors in Vitro

Blood, 2014-12, Vol.124 (21), p.2249-2249

2014

Link zum Volltext

Verfügbarkeit prüfen

The First in Class, Alkylator-Histone-Deacetylase-Inhibitor Fusion Molecule Edo-S101 in Combination with Proteasome Inhibitors Induces Highly Synergistic Pro-Apoptotic Signaling through UPR Activation and Suppression of c-Myc and BCL2 in Multiple Myeloma

Blood, 2016-12, Vol.128 (22), p.4466-4466

2016

Link zum Volltext

Verfügbarkeit prüfen

Is there hope to treat glioblastoma effectively?

CNS oncology, 2015, Vol.4 (6), p.377-379

Mehrling, Thomas

2015

Link zum Volltext

Verfügbarkeit prüfen

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models

Oncotarget, 2018-06, Vol.9 (46), p.28155-28164

2018

Link zum Volltext

Verfügbarkeit prüfen

Activity of the alkylating histone-deacetylase inhibition fusion molecule EDO-S-101 in preclinical models of human glioblastoma independent from MGMT expression

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e13031-e13031

2015

Link zum Volltext

Verfügbarkeit prüfen

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma

Haematologica (Roma), 2014-07, Vol.99 (7), p.1228-1235

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3034: Purine nucleoside phosphorylase regulates metabolic and immune checkpoints

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3034-3034

2022

Link zum Volltext

Verfügbarkeit prüfen

Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis

Kidney international, 2018-11, Vol.94 (5), p.926-936

2018

Link zum Volltext

Verfügbarkeit prüfen

Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study

JNCI cancer spectrum, 2018-10, Vol.2 (4), p.pky038-pky038

2018

Link zum Volltext

Verfügbarkeit prüfen

EDO-S101, an Alkylating-HDAC-Inhibitor, is Synergistic With Proteasome Inhibition Against Multiple Myeloma Through Activation of Multiple Pathways

Clinical lymphoma, myeloma and leukemia, 2017-02, Vol.17 (1), p.e31-e32

2017

Link zum Volltext

Verfügbarkeit prüfen

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM

Blood, 2009-08, Vol.114 (8), p.1563-1575

2009

Link zum Volltext

Verfügbarkeit prüfen

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

Journal of hematology and oncology, 2017-06, Vol.10 (1), p.127-127, Article 127

2017

Link zum Volltext

Verfügbarkeit prüfen

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Blood, 2014-12, Vol.124 (21), p.2100-2100

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(28)

Publikationsform

Sprache

Englisch
(31)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Humans
(8)
Oncology
(6)
Hematology
(4)
Animals
(3)
Apoptosis - Drug Effects
(3)
Benzimidazoles - Pharmacology
(3)
Cancer Therapies
(3)
Edo-S101
(3)
Health Aspects
(3)
Mice
(3)
Alkylation
(2)
Analysis
(2)
Antibodies
(2)
Antibody-Drug Conjugate
(2)
Antineoplastic Agents - Pharmacology
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Apoptosis
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101

Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity

Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11

Chemotherapy is getting 'smarter'

Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies

DDRE-33. PRECLINICAL THERAPEUTIC EFFICACY OF THE NOVEL BLOOD BRAIN BARRIER PENETRANT ATR INHIBITOR LR02 IN GLIOBLASTOMA

Abstract CT023: Dose escalation of tinostamustine in patients with advanced solid tumors

Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity

Edo- S101, a New Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Has Superior Activity Against Myeloma and B Cell Lymphoma and Strong Synergy with Proteasome Inhibitors in Vitro

The First in Class, Alkylator-Histone-Deacetylase-Inhibitor Fusion Molecule Edo-S101 in Combination with Proteasome Inhibitors Induces Highly Synergistic Pro-Apoptotic Signaling through UPR Activation and Suppression of c-Myc and BCL2 in Multiple Myeloma

Is there hope to treat glioblastoma effectively?

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models

Activity of the alkylating histone-deacetylase inhibition fusion molecule EDO-S-101 in preclinical models of human glioblastoma independent from MGMT expression

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

Abstract 3034: Purine nucleoside phosphorylase regulates metabolic and immune checkpoints

Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis

Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study

EDO-S101, an Alkylating-HDAC-Inhibitor, is Synergistic With Proteasome Inhibition Against Multiple Myeloma Through Activation of Multiple Pathways

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Suchergebnisse filtern